PTGX

Protagonist Therapeutics Inc. Common Stock (PTGX)

Stock · NASDAQ · Health Care

$144.15as of 8/28/2026

Active signals

High Beta39.8%
Volume Spike7.5%
Support level
$97.95
Industry
Biotechnology: Pharmaceutical Preparations

How Protagonist Therapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2018 annual results

market-wall.comTotalRevenue$30.93MR&D$59.50M (192%)SG&A$13.70M (44%)Tax$799.0K (3%)PTGX

Source: 10-K filed Mar 12, 2019 · via SEC EDGAR / Finnhub

Protagonist Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • PTGX
    Protagonist Therapeutics Inc. Common Stock
    $144.15
    ▼ 3.58%
    Market cap $9.40BP/E
  • SYRE
    Spyre Therapeutics Inc. Common Stock
    $90.4
    ▼ 3.43%
    Market cap $9.12BP/E
    $14.51$110.18
  • CYTK
    Cytokinetics Incorporated Common Stock
    $72.17
    ▼ 7.36%
    Market cap $10.13BP/E
    $35.22$88.31
  • PRAX
    Praxis Precision Medicines Inc. Common Stock
    $344.95
    ▼ 6.23%
    Market cap $10.32BP/E
  • SMMT
    Summit Therapeutics Inc. Common Stock
    $13.71
    ▼ 4.33%
    Market cap $10.80BP/E
    $12.07$29.23
  • AXSM
    Axsome Therapeutics Inc. Common Stock
    $199.01
    ▼ 3.52%
    Market cap $10.81BP/E
    $112.9$260.19
  • RYTM
    Rhythm Pharmaceuticals Inc. Common Stock
    $107.23
    ▼ 4.71%
    Market cap $7.72BP/E

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
76.12M
Total value held
$7.77B
Institutional holders
319
Top holders this quarter
  • Unknown9.78M
  • Unknown6.35M
  • Unknown5.18M
  • Unknown5.06M
  • Unknown3.60M
  • Unknown3.48M
  • Unknown3.12M
  • Unknown2.89M
  • Unknown2.45M
  • Unknown2.16M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.